Welcome to our dedicated page for Metsera news (Ticker: MTSR), a resource for investors and traders seeking the latest updates and insights on Metsera stock.
Metsera Inc (MTSR) drives innovation in obesity treatment through next-generation peptide therapies, combining cutting-edge science with clinical development rigor. This resource provides essential updates on the company's progress in developing injectable and oral NuSH analog peptides, leveraging proprietary platforms like the MINT peptide library and Half-life Augmentation by Lipid Optimization (HALO) technology.
Discover timely announcements regarding clinical trial milestones, research breakthroughs, and strategic collaborations. The curated news collection serves investors and healthcare professionals seeking to monitor advancements in metabolic disorder treatments, particularly those addressing pharmacokinetic challenges in peptide-based therapies.
All content undergoes strict editorial review to ensure accuracy and relevance. Users benefit from consolidated access to press releases spanning therapeutic development updates, intellectual property developments, and partnership announcements within the biopharmaceutical sector.
Bookmark this page for streamlined tracking of MTSR's progress in creating differentiated obesity treatments through its dual-formulation approach and platform-driven research methodology.
Metsera (NASDAQ:MTSR), a clinical-stage biopharmaceutical company, reported significant progress in its Q2 2025 pipeline for obesity and metabolic disease treatments. The company highlighted positive results for two key programs: MET-097i, a monthly GLP-1 receptor agonist with Phase 3 initiation planned for late 2025, and MET-233i, a monthly amylin analog that achieved 8.4% weight loss in five weeks with a 19-day half-life.
The company maintains a strong financial position with $530.9 million in cash, providing runway into 2027. Q2 2025 saw increased R&D expenses of $60.5 million and a net loss of $68.7 million. Multiple clinical milestones are expected in late 2025, including VESPER-1 data release, 12-week monotherapy data for MET-233i, and preliminary results from their oral peptide program.
Metsera (Nasdaq: MTSR), a clinical-stage biopharmaceutical company focused on developing next-generation medicines for obesity and metabolic diseases, has announced its participation in the Bank of America 2025 Global Healthcare Conference. CEO Whit Bernard will deliver a presentation on Wednesday, May 14, 2025, from 2:20 to 2:35 P.M. PDT (5:20 – 5:35 P.M. EDT). Interested parties can access a live webcast of the presentation through the Events page in the Investors & News section of Metsera's website at investors.metsera.com.
Metsera (NASDAQ: MTSR) reported its Q4 and full year 2024 financial results, highlighting significant progress in its obesity and metabolic disease pipeline. The company's lead candidate MET-097i, a monthly GLP-1 receptor agonist, demonstrated promising Phase 2a results with up to 11.3% mean placebo-subtracted weight loss after 12 weekly doses.
Financial highlights include completion of an IPO raising $316.2 million, extending runway into 2027. Year-end cash position was $352.4 million. Full-year 2024 results showed R&D expenses of $107.5 million and G&A expenses of $26.8 million, with a net loss of $209.1 million.
Key pipeline developments include:
- Multiple Phase 2b trials for MET-097i with readouts expected mid-2025
- MET-233i Phase 1 program progressing with data expected mid-2025
- Oral formulation studies for MET-224o and MET-097o advancing
- Initiation of IND-enabling studies for MET-815i
Metsera (MTSR), a clinical-stage biopharmaceutical company focused on obesity and metabolic diseases, has announced its participation in TD Cowen's 45th Annual Health Care Conference.
The company's CEO, Whit Bernard, is scheduled to deliver a presentation on Tuesday, March 4, 2025, from 1:10 to 1:40 p.m. ET. Investors and interested parties can access a live webcast of the presentation through the Events page in the Investors & News section at investors.metsera.com. The presentation recording will remain accessible for 90 days after the event.
Metsera (NASDAQ: MTSR), a clinical-stage biotech company focused on developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides for obesity treatment, has successfully completed its initial public offering (IPO). The company sold 15,277,778 shares at $18.00 per share, with underwriters exercising their full option to purchase an additional 2,291,666 shares at the same price.
The total gross proceeds from both the initial shares and additional shares amounted to $316.2 million, before deducting underwriting discounts and other expenses. The company's common stock is now trading on the Nasdaq Global Select Market under the ticker symbol 'MTSR'. BofA Securities, Goldman Sachs & Co. , Evercore ISI, Guggenheim Securities, and Cantor served as joint bookrunners for the offering.
Metsera (Nasdaq: MTSR), a clinical-stage biotech company focused on developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides for obesity treatment, has announced the pricing of its initial public offering. The company is offering 15,277,778 shares of common stock at $18.00 per share, expecting to raise gross proceeds of approximately $275.0 million before deducting underwriting costs and expenses.
Trading is set to begin on the Nasdaq Global Select Market under ticker 'MTSR' on January 31, 2025, with the offering expected to close on February 3, 2025. Metsera has granted underwriters a 30-day option to purchase up to an additional 2,291,666 shares at the IPO price. BofA Securities, Goldman Sachs, Evercore ISI, Guggenheim Securities, and Cantor are serving as joint bookrunners.
FAQ
What is the current stock price of Metsera (MTSR)?
What is the market cap of Metsera (MTSR)?
